|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This retrospective analysis compared the treatment efficacy of PEG-IFN-α2b alone in 55 HBeAg-positive CHB patients with different baseline HBsAg levels.
|
25009392 |
2014 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to the rs7574865 GT/TT genotype, the GG genotype (a risk factor of CHB and hepatitis B virus-related hepatocellular carcinoma) was significantly associated with a reduced SVR rate in both patients who received IFNα-2b therapy (21.1% versus 37.2%, P = 0.01) and those who received pegylated IFNα-2a therapy (18.0% versus 41.2%, P = 9.74 × 10(-5) ).
|
26704347 |
2016 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the expression and function of TLR8 in peripheral blood mononuclear cells (PBMCs) of chronic hepatitis B (CHB) patients and its alteration during peg-IFN-α-2a therapy.
|
28236535 |
2017 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data support that SNP rs7574865 is associated with response to PEG-IFN therapy in Thai patients with CHB, regardless of baseline HBeAg status.
|
31421662 |
2019 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNP rs4646536 in the CYP27B1 gene is a predictive factor of response to PEG-IFN therapy in Thai patients with CHB.
|
28291736 |
2017 |
|
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone.
|
29091327 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB.
|
29456079 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, ss469415590 genotypes were not associated with response to PEG-IFN in Thai patients with HBeAg-positive and HBeAg-negative CHB.
|
26225703 |
2015 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years.
|
31487005 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation.
|
17604363 |
2007 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of anti-IFN antibodies was assessed at baseline and at 3 and 6 months post-treatment in 323 CHB patients treated with PEG-IFN for 1 year.
|
24296674 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding these factors can help determine personalized PEG-IFN therapy for CHB patients.
|
24373087 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the limited efficacy is the main factor restricting the use of PEG-IFNα in CHB and therefore identifying the predictors of response is of great clinical importance.
|
24373089 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients.
|
29790851 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study.
|
28988797 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor.
|
24316030 |
2014 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even after stimulation by TLR agonists, no change was found in IFN-α production in CHB patients.
|
27658394 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB.
|
23553752 |
2013 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peg-IFN-α monotherapy is a treatment option recommended by local and international clinical practice guidelines to help more CHB patients achieve a sustained off-treatment virological response, which is particularly appropriate for relatively young patients who demand a finite treatment approach.
|
31380584 |
2019 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
|
26376789 |
2016 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated.
|
29879024 |
2018 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα.
|
27839836 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate the involvement of miR-548j in aberrant production of type I IFN in CHB patients, and provide a potential target for developing anti-HBV therapies.
|
28342861 |
2017 |
|
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml.
|
29438098 |
2018 |